[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-diagnosis":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,64,94,126,156,190,246,273,297,323,347,381,408,430,455,481,506,542,568,594,623,647,670,719,738],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":42,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100644985","clonal-hematopoiesis-chemotherapy-and-radiation-effects-study-100644985",false,"NCT07675967","Clonal Hematopoiesis Chemotherapy and Radiation Effects Study","CH CARE","Inclusion Criteria:\n\n* Participants to be included in this study include the following:\n* Adults age \\>18 years\n* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)\n* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).\n* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.\n\nExclusion Criteria:\n\n* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure\n* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)\n* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.","ALL","18 Years",{"count":20,"type":21},5000,"ESTIMATED","OBSERVATIONAL","The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.\n\nThe study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).\n\nUltimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Lung Cancer (Diagnosis)","Osteochondroma","Spitz Nevus","Solid Cancers","Breast Cancer","Gastric (Stomach) Cancer","Colorectal (Colon or Rectal) Cancer","Sarcoma","Ovarian Adenocarcinoma","Uterine Adenocarcinoma","Endometrial Adenocarcinoma","Esophageal Adenocarcinoma","Head and Neck Cancer","Therapy-Related Acute Myeloid Leukemia","Therapy-Related MDS","Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Clonal Cytopenia of Undetermined Significance",[43,44,45,46,47,48,49,50],"Adult cancer survivors","Precursor Lesions","clonal hematopoiesis","chemotherapy","radiation","therapy-related myeloid neoplasms","CCUS","clonal hematopoiesis of indeterminate potential","RECRUITING","2026-06-29",{"date":54,"type":55},"2026-06-30","ACTUAL",{"date":57,"type":55},"2025-04-04",{"date":59,"type":21},"2035-03-31",{"name":61,"class":62},"Dana-Farber Cancer Institute","OTHER",1,{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":63},"100623196","effect-of-apneic-oxygenation-of-the-non-ventilated-lung-during-lung-cancer-surgery-100623196","NCT07393490","Effect of Apneic Oxygenation of the Non-ventilated Lung During Lung Cancer Surgery.","The Effect of Apneic Oxygenation of the Non-ventilated Lung on the Expression of Hypoxia-inducible Factor-1 Alpha (HIF-1α) and Interleukin-6 (IL-6) in Lung Tissue During Lung Cancer Surgery.","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Patients scheduled to undergo surgical resection of a single lung segment for lung cancer\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Chronic corticosteroid therapy and\u002For other immunomodulatory treatments\n* Severe pulmonary diseases, including:\n\nChronic obstructive pulmonary disease classified as GOLD stage 3-4 (Global Initiative for Chronic Obstructive Lung Disease).\n\nSevere asthma according to GINA classification (Global Initiative for Asthma), step 4.\n\nSevere interstitial lung disease defined by: Forced vital capacity (FVC) \\\u003C 50% predicted, diffusing capacity of the lung for carbon monoxide (DLCO) \\\u003C 40% predicted, presence of extensive pulmonary fibrosis on computed tomography (CT)\n\n* Surgical procedure expected to last less than 2 hours\n* Intraoperative hemodynamic instability, defined as: Mean arterial pressure \\\u003C 60 mmHg for more than 30 minutes despite adequate volume resuscitation, requirement for high-dose vasopressor support (norepinephrine \\> 0.2 µg\u002Fkg\u002Fmin)\n* New-onset intraoperative cardiac arrhythmias\n* Significant intraoperative blood loss, defined as the need for transfusion of more than two units of packed red blood cells\n* Intraoperative ventilatory instability, defined as: Severe hypoxemia (PaO₂ \\\u003C 60 mmHg or SpO₂ \\\u003C 85% with FiO₂ 1.0), hypercapnia (PaCO₂ \\> 70 mmHg with pH \\\u003C 7.2), inability to achieve adequate ventilation.",{"count":72,"type":21},56,"INTERVENTIONAL",[75],"NA","This study investigates the effect of apneic oxygenation of the non-ventilated lung on local and systemic inflammatory response during lung cancer surgery.\n\nPatients undergoing surgical resection of lung cancer often require one-lung ventilation during anaesthesia. This results in alveolar hypoxia accompanied by upregulated expression of inflammatory markers. Apneic oxygenation of the non-ventiladed lung may influence inflammatory processes and oxygenation during surgery. The aim of this study is to evaluate whether apneic oxygenation affects inflammatory markers in lung tissue and postoperative recovery in patients undergoing lung cancer surgery. The study is conducted at a single center and includes adult patients scheduled for elective lung cancer surgery. Data will be collected durig the perioperative period. The results of this study may contribute to improved anaesthetic management and patient outcomes during thoracic surgery.",[25],[79,80,81,82,83,84],"One-lung ventilation","Apneic oxygenation","Inflammatory response","Hif 1 alpha","Interleukin 6","Thoracic anaesthesia","2026-06-24",{"date":87,"type":55},"2026-06-26",{"date":89,"type":55},"2025-01-02",{"date":91,"type":21},"2026-09",{"name":93,"class":62},"Osijek University Hospital",{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":22,"phases":4,"briefSummary":105,"conditions":106,"keywords":113,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100644397","feasibility-and-preliminary-performance-of-an-ai-prototype-for-digital-rose-during-ebus-tbna-and-peripheral-tbna-a-prospective-pilot-study-ai-rose-feas-100644397","NCT07662967","Feasibility and Preliminary Performance of an AI Prototype for Digital ROSE During EBUS-TBNA and Peripheral TBNA: a Prospective Pilot Study (AI-ROSE-FEAS)","Preliminary Feasibility and Diagnostic Performance of an Investigational Artificial Intelligence Prototype for Digital Rapid On-Site Evaluation (ROSE) of Cytological Slides During Diagnostic Bronchoscopy With Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) and Peripheral Transbronchial Needle Aspiration: a Prospective Monocentric Pilot Study (AI-ROSE-FEAS)","AI-ROSE-FEAS","Inclusion Criteria\n\n* Age ≥ 18 years.\n* Clinical indication for diagnostic bronchoscopy with EBUS-TBNA for mediastinal lymphadenopathy and\u002For TBNA on peripheral lung lesions, according to ACCP\u002FERS-ESTS guidelines and the Unit's diagnostic pathways.\n* The procedure will be performed in two-person mode with IP-ROSE performed as per the center's SOP.\n* Ability to provide written informed consent.\n* Willingness to undergo the required follow-up.\n\nExclusion Criteria\n\n* Absolute contraindications to bronchoscopy.\n* Known histological diagnosis of the target lesion (except re-staging).\n* Concomitant interventional procedures that alter the standard sequence.\n* Inability to provide written informed consent.\n* Any condition that, in the investigator's judgment, compromises patient safety or the reliability of the data.",{"count":103,"type":21},65,"6 Months","Rapid On-Site Evaluation (ROSE) of cytological slides obtained during EBUS-TBNA improves diagnostic yield by providing real-time adequacy assessment and preliminary diagnostic orientation after each needle pass. In centers without a dedicated cytopathologist, ROSE is performed by a second interventional pulmonologist acting as a dedicated ROSE operator (interventional pulmonologist-performed ROSE, IP-ROSE), a model associated with good but variable diagnostic performance compared to cytopathologist-performed ROSE.\n\nThis study evaluates the feasibility and preliminary diagnostic performance of an investigational artificial intelligence prototype for digital ROSE. The prototype, developed in-house by the Principal Investigator, analyzes microscopic images of Diff-Quik stained cytological slides acquired through a dedicated digital microscope, together with basic clinical data, via API calls to a multimodal AI model. It produces two outputs: sample adequacy (appropriate\u002Fnot appropriate) and malignancy suspicion (benign\u002Fmalignant), each with a confidence score. The AI output is recorded in the study database for research purposes only and is not shown to the operator in real time; it does not influence clinical decisions during the procedure.\n\nThe study is a prospective, monocentric, observational pilot study enrolling 65 adult patients undergoing EBUS-TBNA or peripheral TBNA with IP-ROSE at a single interventional pulmonology unit. The primary statistical unit is the individual ROSE slide, with an expected 130 to 160 evaluable slides. Co-primary endpoints are: (1) technical feasibility of the AI prototype, defined as the proportion of slides with valid AI output within 90 seconds; and (2) AI accuracy for sample adequacy assessment compared to the definitive cytopathological diagnosis, with an expected 95% confidence interval precision of ±5.5%. Secondary endpoints include AI accuracy for malignancy suspicion, agreement between the AI prototype and the IP-ROSE operator, and AI output latency.\n\nThe AI prototype is not a commercially approved or CE-marked medical device. It was developed internally by the Principal Investigator for research purposes and is evaluated exclusively within this study. Data from this pilot study will inform the design of a subsequent confirmatory non-inferiority trial, which will be the subject of separate registration and ethical approval.",[107,108,109,110,111,112,25],"Lung Neoplasms","Bronchoscopy","AI (Artificial Intelligence)","Mediastinal ( Chest) Masses","Mediastinal Lymphadenopathy","EBUS Guided Transbronchial Needle Aspiration",[114,115],"bronchoscopy","artificial intelligence","NOT_YET_RECRUITING","2026-06-17",{"date":119,"type":55},"2026-06-23",{"date":121,"type":21},"2026-07-01",{"date":123,"type":21},"2027-03",{"name":125,"class":62},"Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":73,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":155},"100605935","evaluate-the-clinical-performance-of-the-flow-cytometry---flowpath-lung-test-as-a-sensitive-and-specific-non-invasive-diagnostic-of-sputum-samples-to-identifydetect-the-presence-of-lung-cancer-in-high-risk-individuals-who-have-existing-lung-nodules-6-to-30-mm-in-diameter-determined-by-ldct-100605935","NCT07168993","Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify\u002FDetect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to \u003C30 mm in Diameter, Determined by LDCT.","Detection of Early-Stage Lung Cancer in Sputum Using Flow Cytometry and an Automated Analysis Pipeline","BA-004","Inclusion Criteria:\n\n1. Is able to give signed informed consent and comply with study requirements.\n2. Is high risk for getting lung cancer:\n\n   1. ≥50 - 80 years of age.\n   2. current smoker with smoking history of at least 20 pack-years or current non-smoker with smoking history of at least 20 pack-years who quit smoking within the past 15 years.\n3. Has a \\>6 to \\\u003C30 mm diameter lung nodule (found by lung cancer screening or found incidentally by CT scan) as determined by CT and is willing to provide a sputum sample for FlowPath Lung test within 6 weeks of the prestudy baseline CT scan.\n\n3a) Nodule is either new, increasing, or stable for ≤ 6 months. 3b) In cases where a person has multiple nodules as determined by CT scan, the subject's most suspicious nodule is \\>6 to \\\u003C30 mm in diameter.\n\n4\\) Is willing to provide contact information to the study PI or the treating physician(s) who can release required medical information related to SOC follow-up.\n\nExclusion Criteria:\n\n1. Is unable to cough with sufficient exertion to produce a sputum sample (e.g., due to severe obstructive lung disease).\n2. The dominant nodule is ground glass or part solid as determined by CT scan.\n3. Has 5 or more nodules sized \\>4 mm.\n4. The nodule sized \\>6 to \\\u003C30 mm in diameter is a distal (subsegmental) endobronchial nodule or a perifissural nodule.\n5. Is immunosuppressed.\n6. Has rheumatoid arthritis.\n7. Had lung cancer diagnosis in the past 5 years or any other cancer (other than non-melanoma skin cancer) in the past 2 years. A subject on long-term medications used for prevention of cancer, such as Tamoxifen for breast cancer, is not excluded.\n8. Has angina with minimal exertion.\n9. Is currently pregnant or planning on becoming pregnant during this study.","50 Years","80 Years",{"count":137,"type":21},2063,[75],"Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \\>6 to \\\u003C30 mm in Diameter, Determined by LDCT.",[25],[142,143,144],"Lung Cancer","Diagnostic Test","Sputum Assay","2026-06-09",{"date":147,"type":55},"2026-06-10",{"date":149,"type":55},"2026-02-25",{"date":151,"type":21},"2029-07-01",{"name":153,"class":154},"bioAffinity Technologies Inc.","INDUSTRY",7,{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":73,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":63},"100593071","investigation-of-the-effects-of-tele-yoga-training-in-individuals-with-lung-cancer-undergoing-lung-resection-surgery-100593071","NCT07001670","Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection Surgery","The Effects of an 8-Week Tele-Yoga Program on Postoperative Recovery in Patients With Lung Cancer Undergoing Lung Resection","Inclusion Criteria:\n\n* Aged between 18 and 65 years,\n* Histologically confirmed diagnosis of Stage I-IIIA lung cancer according to the 9th edition of the AJCC Cancer Staging Manual,\n* Underwent lobectomy, pneumonectomy, segmentectomy, or wedge resection via video-assisted thoracoscopic surgery (VATS) or robot-assisted thoracoscopic surgery (RATS),\n* An estimated life expectancy of ≥6 months,\n* Karnofsky Performance Status score greater than 80% at study entry,\n* Possession of the necessary equipment and access to a stable internet connection to enable participation in online interventions.\n\nExclusion Criteria:\n\n* History of receiving radiotherapy or chemotherapy prior to surgery,\n* Presence of severe dysfunction in vital organs such as the heart, brain, kidneys, or others,\n* Having any comorbid condition that contraindicates participation in an exercise training program,\n* Presence of serious postoperative complications,\n* Cognitive impairments that hinder effective communication,\n* Current participation in a structured and regular exercise program,\n* Missing three consecutive weeks of sessions or completing less than 75% of the prescribed exercises,\n* Voluntary withdrawal from the study by the participant.","65 Years",{"count":165,"type":21},40,[75],"This randomized controlled clinical trial aims to evaluate the effects of an 8-week tele-yoga intervention in individuals with lung cancer who have undergone lung resection surgery. The intervention group will receive supervised yoga sessions via online synchronous video conferencing, while the control group will continue with standard post-operative care. The primary outcome is exercise capacity (6-minute walk test), with secondary outcomes including pulmonary function, respiratory and peripheral muscle strength, physical activity level, dyspnea, fatigue, sleep quality, anxiety and depression, and quality of life. It is hypothesized that tele-yoga will improve physical and psychological recovery post-surgery and may serve as a feasible home-based pulmonary rehabilitation alternative.",[169,25],"Postoperative Period",[171,172,173,174,175,176,177,178,179,180,181],"Exercise capacity","Pulmonary function","Muscle Strength","Dyspnea","Fatigue","Anxiety","Depression","Quality of Life","Exercise Therapy","Telemedicine","Rehabilitation","2026-06-06",{"date":145,"type":55},{"date":185,"type":55},"2025-06-10",{"date":187,"type":21},"2026-10-10",{"name":189,"class":62},"Istanbul University",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":200,"studyType":22,"phases":4,"briefSummary":201,"conditions":202,"keywords":215,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":241,"leadSponsor":243,"locationsCount":245},"100642988","registry-of-minimally-invasive-cancer-treatment-using-spectral-angio-ct-image-guidance-100642988","NCT07636148","Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance","Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice","PreciseOnco","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;\n* Use of spectral angio-CT image guidance as part of standard care;\n* Written confirmed consent.\n\nExclusion Criteria:\n\n* Patients who are declared incapacitated;\n* Patients suffering from psychic disorders that make a comprehensive judgement impossible.",{"count":199,"type":21},2000,"3 Years","This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.\n\nDuring these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.\n\nNo experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.",[203,25,204,205,206,207,208,209,210,211,212,213,214],"Liver Cancer (Primary and Metastatic)","Bone Cancer Metastatic","Bone Cancer Tumor","Kidney Tumors","Renal Cancer","Hepatocellular Carcinoma (HCC)","Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Musculoskeletal Cancers","Musculoskeletal Tumors","Bone Tumors","Lung Tumors",[216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237],"Spectral CT","Dual-layer detector CT","Angio-CT","Image-guided therapy","Interventional oncology","Thermal ablation","Radiofrequency ablation","Microwave ablation","Cryoablation","Transarterial chemoembolization","Transarterial radioembolization","Transarterial embolization","Local tumor control","Tumor recurrence","Progression-free survival","Hepatocellular carcinoma","Liver metastases","Renal cell carcinoma","Lung tumors","Musculoskeletal tumors","Registry","Multicenter","2026-06-03",{"date":145,"type":55},{"date":121,"type":21},{"date":242,"type":21},"2030-12-31",{"name":244,"class":62},"Mark C Burgmans, MD PhD",3,{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":17,"minAge":134,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":73,"phases":255,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":272},"100635430","blood-based-risk-evaluation-with-ai-for-targeted-primary-health-care-in-early-lung-cancer-detection-100635430","NCT07552584","Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection","BREATHE","Inclusion Criteria:\n\n* Diagnosed with COPD.\n* =\\> 50 years.\n* Former or current smoker.\n* Speaks and understands Danish.\n* Able to give informed consent to participation.\n\nExclusion Criteria:\n\n* Had a CT scan of the thorax within 6 months.\n* Received active treatment for cancer within one year (except non-melanoma skin cancer and carcinoma in situ cervicis uteri).\n* Diagnosed with cancer within one year (except non-melanoma skin cancer and carcinoma in situ cervicis uteri).\n* Presents with symptoms giving suspicion of cancer (except non-melanoma skin cancer and carcinoma in situ cervicis uteri).\n* In a condition not allowing diagnostic workup for or treatment of lung cancer.\n* Does not have Eboks (electronic communication with Danish authorities).",{"count":254,"type":21},1000,[75],"The study is a prospective, non-randomized feasibility study evaluating blood sample and machine learning-based risk stratification for lung cancer in patients with COPD (chronic obstructive pulmonary disease).\n\nPatients with COPD will be recruited in general practice, where they will have a blood sample drawn. All data will be analyzed by the machine learning model, and patients with increased risk of lung cancer will be referred for a low-dose CT scan of the chest.\n\nThe primary objective of the study is to evaluate the feasibility of AI and DNA methylation-based risk stratification for lung cancer in patients with COPD in a primary care setting.\n\nThe secondary objectives are to evaluate the safety of the risk stratification approach, the potential effects on quality of life and wellbeing, to gain insight into the patient and physician perspectives, and to estimate the health economic consequences.",[25],[259,260,261,262,263],"Lung cancer","Biomarkers","Machine learning","Risk stratification","COPD","2026-06-02",{"date":238,"type":55},{"date":267,"type":55},"2026-05-26",{"date":269,"type":21},"2034-04",{"name":271,"class":62},"Vejle Hospital",2,{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":73,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":296},"100559048","evaluating-the-implementation-of-a-comprehensive-multilevel-virtual-oncology-program-among-veterans-diagnosed-with-lung-colorectal-prostate-and-breast-cancers-in-the-us-department-of-veterans-affairs-100559048","NCT06559059","Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs","Patients Inclusion Criteria:\n\n1. A Veteran\n2. Aged 18 years or older\n3. Newly diagnosed with lung, prostate, breast, or colon cancer within 3 months of telemedicine visit\n4. Engaged in an oncology visit during the 36-month analysis period at a Veterans Affairs Medical Center (VAMC) location.\n\nVAMC Providers and Staff Inclusion Criteria:\n\n1. Provider or staff member at one of the VAMC locations including physicians, nurse practitioners, physicians' assistants, and nurses caring for Veterans\n2. Providers or staff members having helped provide care for at least 5 Veterans with cancer in the previous 6 months at a VAMC location\n\nPatients Exclusion Criteria:\n\n1. Veterans who have not seen any providers in the VA within the past year\n2. Patients previously diagnosed with lung, prostate, breast, or colon cancer\n3. Pregnant patients\n\nVAMC Providers and Staff Exclusion Criteria:\n\n1\\. Providers or staff members who do not help treat Veterans with specified cancers in oncology at the VA",{"count":280,"type":21},1800,[75],"The objective of the pragmatic trial to test the effectiveness of an existing, ongoing clinical service, the VA National TeleOncology program (NTO), a multilevel telehealth population health management program. The primary aims are to study the intervention and determine its effectiveness on telehealth engagement, clinical quality, and healthcare cost outcomes across personal characteristics.",[284,285,286,287],"Lung Cancer Diagnosis","Colorectal Cancer (Diagnosis)","Prostate Cancer Diagnosis","Breast Cancer Diagnosis","2026-06-01",{"date":238,"type":55},{"date":291,"type":55},"2024-06-18",{"date":293,"type":21},"2027-07-31",{"name":295,"class":62},"NYU Langone Health",5,{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":305,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":63},"100639916","non-invasive-malignancy-classifiers-using-blood-biomarkers-for-lung-nodule-evaluation-100639916","NCT07623473","Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE","Inclusion Criteria:\n\n* Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit\n* Having signed informed consent\n\nExclusion Criteria:\n\n* Active cancer, excluding non-melanoma skin cancer\n* Comorbidities that exclude the patient from clinical follow-up and final diagnosis",true,{"count":280,"type":21},"The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.\n\nEach blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.",[25,309],"Nodule, Solitary Pulmonary",[260,311,312,313,314],"Lung nodule","Fragmentomics","Methylome","Cell-free DNA","2026-05-29",{"date":238,"type":55},{"date":318,"type":55},"2024-05-22",{"date":320,"type":21},"2028-02-01",{"name":322,"class":62},"Herlev and Gentofte Hospital",{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":73,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":63},"100600796","telehealth-collaborative-care-model-cocm-in-lung-cancer-100600796","NCT07102147","Telehealth Collaborative Care Model (CoCM) in Lung Cancer","Increasing Adoption of a Telehealth-Delivered Collaborative Care Program for Patients With Lung Cancer: A Pilot Study","Inclusion Criteria:\n\n* Are aged 18 years or older.\n* Are currently being seen by Penn Medicine Thoracic Oncology for lung cancer treatment or survivorship care.\n* Are referred to collaborative care by a Penn Medicine Thoracic Oncology clinician for treatment of depression, anxiety, or other psycho-therapy services.\n\nExclusion Criteria:\n\n* Are already receiving psycho-therapy treatment services outside of Penn Medicine's collaborative care program, Penn Integrated Care (PIC).\n* Have a significant and\u002For untreated medical and\u002For psychiatric co-morbidity (e.g., other cancers, schizophrenia, acute suicidal and\u002For homicidal ideation) that make them ineligible for the Penn CoCM program.",{"count":331,"type":21},30,[75],"The goal of this trial is to compare the impact of two outreach strategies (high touch vs. standard outreach) on a collaborative care program delivered via telehealth to patients with lung cancer.",[25,176,335],"Depression in Adults",[259,176,177,337],"Collaborative care","2026-05-27",{"date":340,"type":55},"2026-05-28",{"date":342,"type":55},"2025-08-18",{"date":344,"type":21},"2027-06-30",{"name":346,"class":62},"Abramson Cancer Center at Penn Medicine",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":73,"phases":357,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":63},"100612520","combination-versus-alone-liposomal-bupivacaine-blocks-in-minimally-invasive-thoracic-surgery-1-100612520","NCT07254650","Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1","A Phase IIb, Randomized, Double-Blinded, Three-Arm Clinical Trial: The Study of Liposomal Bupivacaine Via Intercostal Nerve Block, Serratus Anterior Plane Block, or Combination Block for Pain Control After Robotic Thoracic Surgery","CALMS-1","Inclusion Criteria:\n\n* Plan to undergo planned (elective) minimally invasive isolated R-VATS procedure, to include pulmonary anatomic resections (anatomic lobectomy, segmentectomy, and wedge resection if performed robotically)\n* Age ≥ 18 years old\n* Ability to understand and capacity\u002Fwillingness to sign a written informed consent form\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Unwilling to sign informed consent form, mentally challenged\u002Fdelayed, or lacking capacity\u002Funable to consent to participation in the trial own their own behalf\n* Vulnerable populations\n* Incarcerated individuals\n* Pregnant individuals\n* Breastfeeding individuals\n* Individuals with potentially altered pharmacokinetics and metabolism of study drugs\n* Renal failure: creatinine ≥ 2, or glomerular filtration rate \\\u003C 45 mL\u002Fmin\n* Hepatic failure: serum ammonia \\> 33 mcg\u002FdL and\u002For Child-Pugh \\> A\n* Individuals suffering from chronic pain\n* Individuals taking pre-operative narcotics\n* Patients undergoing emergent surgery or urgent surgery for acute, traumatic injuries\n* Patients undergoing extra-pleural resections, chest wall resection, pleurectomies, pleurodesis, and decortications\n* Planned concurrent abdominal procedure: for example, but not limited to, an esophagectomy\n* Patients requiring subcostal transversus abdominis plane (TAP) block\n* Use of a rib spreader during thoracic procedure\n* Patients admitted to the intensive care unit (ICU) post-operatively while sedated and intubated\n* Patients with major post-operative complications\n* Wedge resection for pulmonary bleb\n* Unanticipated pleurectomy, even if partial\n* Surgeon injects superficial wounds with LipoB",{"count":356,"type":21},300,[75],"The goal of this clinical trial is to assess how the location of local anesthetic medication affects pain control capabilities in adult patients undergoing thoracic(chest)-only minimally invasive surgery. The main questions it aims to answer are:\n\n* Is pain decreased when local analgesia is provided as a combination of serratus anterior plane block and intercostal nerve block when compared to either block administered individually?\n* How does location of local analgesia administration impact length-of-stay, cost-of-care, and quality-of-life?\n\nResearchers will compare three treatment options including long-acting local anesthetic (Exparel®) administered as (1) intercostal nerve block, (2) serratus anterior plane block, or (3) combination of intercostal nerve block and serratus anterior plane block to see if pain and opioid use are reduced dependent upon treatment group.\n\nAll participants will receive a local anesthetic nerve block. Participants will be asked to describe their pain after surgery and to answer various questionnaires before and after surgery.",[25],[361,362,363,364,365,366,367,368,369,370,371,372,373],"Exparel®","Liposomal Bupivacaine","Multi-Level Intercostal Nerve Block","Serratus Anterior Plane Block","Robotic-Assisted Thoracic Surgery","Adult","Pulmonary Wedge Resection","Lobectomy","Pulmonary Segmentectomy","Pneumonectomy","Minimally-Invasive Thoracic Surgery","Pain Control","Regional Anesthetic Block",{"date":340,"type":55},{"date":376,"type":21},"2026-06",{"date":378,"type":21},"2028-01-01",{"name":380,"class":62},"University of Texas Southwestern Medical Center",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":73,"phases":390,"briefSummary":391,"conditions":392,"keywords":396,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":272},"100617211","acupressure-for-cough-in-lung-cancer-survivors-100617211","NCT07315672","Acupressure for Cough in Lung Cancer Survivors","Acupressure for Cough in Lung Cancer Survivors: A Randomized Controlled Trial","Inclusion Criteria:\n\n* be at least 18 years of age;\n* have a diagnosis of LC at any stage and of any pathological type;\n* have a cough symptom rating ≥3 on a 0 to 10 numeric rating scale within 7 days preceding enrollment;\n* can perform acupressure independently in daily activities;\n* be able to read Chinese and communicate in Cantonese or Mandarin;\n* be able to provide informed consent.\n\nExclusion Criteria:\n\n* have unstable chronic diseases other than LC;\n* have received acupressure or acupuncture within the three months preceding study enrollment;\n* have serious illnesses or other conditions that prevent the participants from following the intervention protocols;\n* have a life expectancy of less than 3 months;\n* Be currently participating in other research programs that may affect the outcomes under investigation.",{"count":389,"type":21},80,[75],"The goal of this randomized controlled trial is to examine the effect of an acupressure intervention in alleviating cough and reducing co-occurring symptoms (dyspnea, cough, and fatigue) in patients with lung cancer.\n\nThe hypotheses are:\n\n1. Acupressure can alleviate cough in lung cancer survivors;\n2. Acupressure can reduce a cough-related symptom cluster (dyspnea-cough-fatigue) experienced by lung cancer survivors;\n3. Acupressure can reduce the symptom burden and improve the health-related quality of life and functional capacity of lung cancer survivors experiencing cough.\n\nParticipants will:\n\nReceive acupressure for 8 weeks or receive an education booklet; Keep a diary of their acupressure practice and symptoms; Be assessed at baseline (T0), early intervention (T1), post-intervention (T2), and 8 weeks after the intervention period (T3).",[25,393,394,395],"Acupressure","Coughing","Symptom Cluster",[393,397,142,174,395,398,175,178],"Cough","Symptom Burden","2026-05-20",{"date":401,"type":55},"2026-05-22",{"date":403,"type":55},"2026-03-09",{"date":405,"type":21},"2027-02",{"name":407,"class":62},"The University of Hong Kong",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":305,"sex":415,"minAge":18,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":73,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":272},"100640825","promoting-radon-testing-among-mothers-of-young-children-100640825","NCT07591389","Promoting Radon Testing Among Mothers of Young Children","Promoting Radon Testing Among Mothers of Young Children: A Translational Clinical Trial","Inclusion Criteria:\n\n* Participants are female mothers of children aged 4 and under.\n* Participants own a smartphone.\n* Children brought in for appointments are their biological or adoptive child.\n\nExclusion Criteria:\n\n* Previous testing for radon within the past two (2) years.\n* The mother's child brought in for the appointment is over 4 years of age.","FEMALE",{"count":417,"type":21},100,[75],"Radon is the second-leading cause of lung cancer after smoking and may contribute to other cancer deaths; children are especially vulnerable due to a larger lung surface area and higher respiratory rates. The goal of this research is to test the feasibility of the radon app to promote radon testing among mothers of children aged 4 or younger when they receive a free radon test kit.",[25],"2026-05-12",{"date":423,"type":55},"2026-05-15",{"date":425,"type":55},"2026-04-10",{"date":427,"type":21},"2026-12",{"name":429,"class":62},"University of North Dakota",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":305,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":63},"100625752","a-study-measuring-markers-of-airway-inflammation-in-breath-samples-from-people-with-respiratory-diseases-and-healthy-volunteers-100625752","NCT07426718","A Study Measuring Markers of Airway Inflammation in Breath Samples From People With Respiratory Diseases and Healthy Volunteers.","An Expanded inVestigation of Inflammacheck™ to Measure Exhaled Breath CondensaTe Hydrogen perOxide in RespiratorY Conditions A Cross-sectional, Observational Study Comparing Exhaled Breath Biomarkers Across Respiratory Diseases and Healthy Volunteers.","VICTORY 2","Inclusion Criteria:\n\n\\- 1. Age: Adults aged ≥18 years. 2. Consent: Willing and able to provide written informed consent (prospective participants only).\n\n3\\. Clinical status: Belong to one of the defined diagnostic categories listed below:\n\n1. Group A: Lung cancer confirmed by multidisciplinary team (MDT) diagnosis.\n2. Group B: Suspected lung cancer (biopsy negative or awaiting further investigation).\n3. Group C: Pneumonia (radiologically or clinically confirmed).\n4. Group D: Non-malignant airways diseases (asthma or COPD).\n5. Group E: Other non-malignant respiratory diseases (interstitial lung disease, bronchiectasis, breathing pattern disorder).\n6. Group F: Healthy controls with no known respiratory disease. 4. Clinical documentation: Availability of relevant diagnostic and demographic data to confirm disease classification (for retrospective participants).\n\n   5\\. Previous participation: Individuals previously enrolled in the VICTORY or ExPeL studies may be included for retrospective data integration.\n\n   6\\. Willing and able to perform a breath test using the Inflammacheck® device. 7. Willing to allow access to relevant clinical data and imaging results 8. Be able to understand and communicate in English with or without the need for a translator, to ensure informed consent and comprehension of study procedures\n\n   Exclusion Criteria:\n   * 1\\. Active respiratory infection (e.g., tuberculosis, bronchopneumonia) other than pneumonia (e.g., tuberculosis) at the time of breath sampling.\n\n     2\\. History of major thoracic surgery or lung resection within the previous six months.\n\n     3\\. Current or recent chemotherapy or radiotherapy for lung cancer at the time of breath sampling (except for retrospective confirmed cancer cases where data were collected pre-treatment).\n\n     4\\. Severe cognitive impairment, communication barriers, or any condition preventing informed consent or compliance with study procedures.\n\n     5\\. Pregnancy or breastfeeding. 6. Active use of cannabis or recreational drugs known to alter exhaled breath composition.\n\n     7\\. Current active tobacco smoking within the past 12 hours prior to breath collection will be an exclusion criterion, as will the use of vaping or e-cigarettes within this period, to prevent contamination of exhaled breath samples 8. Participants who have taken systemic antibiotics or commenced a new course of oral or inhaled corticosteroids within the preceding two weeks will also be excluded, as these may transiently alter inflammatory biomarkers in exhaled breath (this is not applicable to participants with pneumonia). Stable use of maintenance inhaled corticosteroids in patients with chronic respiratory conditions (e.g., asthma, COPD) will be permitted, provided dosing has remained unchanged for at least four weeks prior to sampling.\n\n     9\\. Any condition that, in the opinion of the investigator, could compromise participant safety or the integrity of the data.\n\n     10\\. Unable or unwilling to provide informed consent. 11. Unable to complete the breath test due to physical or cognitive limitations.\n\n     12\\. Currently participating in another interventional clinical trial that may confound breath biomarker data.\n\n     13\\. Received systemic treatment for lung cancer prior to breath sampling (for the lung cancer group only).\n\n     14\\. History of any active cancer within the past 12 months (excluding basal cell carcinoma of the skin or cervical carcinoma in situ), except for those in the confirmed lung cancer group.\n\n     15\\. They have any active respiratory infection other than pneumonia (e.g., tuberculosis) at the time of breath sampling.\n\n     16\\. They have undergone a bronchoscopy or invasive respiratory procedure within the past 48 hours, due to the potential for artefacts in breath data.\n\n     17\\. Pneumonia with concurrent lung cancer, thoracic malignancy or lung fibrosis. Pneumonia with co-existent asthma or COPD can be included at discretion of the PI.",{"count":439,"type":21},140,"Lung cancer remains the leading cause of cancer-related death in the UK, with over 35,000 deaths annually and most cases diagnosed at a late stage. Current screening programmes using low-dose CT scans target only high-risk individuals, missing around 30% of lung cancer cases, including many women and never-smokers. There is no simple, non-invasive tool to help triage patients with persistent respiratory symptoms who fall outside formal screening criteria. Inflammacheck® measures hydrogen peroxide and other breath biomarkers linked to airway inflammation and oxidative stress. Preliminary studies (VICTORY and ExPeL) have shown strong diagnostic performance for distinguishing lung cancer from other respiratory conditions. VICTORY 2 aims to validate and refine the AI model supporting Inflammacheck®, enabling accurate, rapid, and affordable triage for suspected lung cancer in NHS settings.",[25,442,443,444],"Lung Cancer (Suspected or Confirmed)","Healthy","Pneumonia","2026-05-05",{"date":447,"type":55},"2026-05-08",{"date":449,"type":55},"2026-03-05",{"date":451,"type":21},"2026-12-30",{"name":453,"class":454},"Portsmouth Hospitals NHS Trust","OTHER_GOV",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":462,"targetDuration":104,"studyType":22,"phases":4,"briefSummary":463,"conditions":464,"keywords":468,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":63},"100639257","3d-us-construct-on-volumetric-assessment-of-lung-disease--clinical-application-100639257","NCT07574255","3D-US Construct on Volumetric Assessment of Lung Disease & Clinical Application","Three-dimensional Ultrasonic Construct on Volumetric Assessment of Lung Disease and Its Clinical Application","Inclusion Criteria:\n\n* Participants suspect with lung lesions referred for ultrasound workup\n\nExclusion Criteria:\n\n* Participants aged \\\u003C 18 years\n* Participants refusal\n* Participants with implanted metal in scanning area interfering data collection\n* Participants who cannot perform breath holding for at least 1 second",{"count":356,"type":21},"The goal of this observational study is to establish the three-dimensional construct of lung lesion via ultrasound in patients with peripheral lung lesions or any superficial lesion in thoracic fields. The primary question our study aims to answer is:\n\nWhether the 3D ultrasound morphology can reflect lung disease entities? Whether the 3D volumetric follow-up protocol can be standardised to reflect lung disease status?",[465,25,466,467],"Lung Ultrasound","Peripheral Lung Lesions","Ultrasound Assessment",[469,470,471],"lung ultrasound","three-dimensional ultrasound","peripheral lung lesions","2026-05-03",{"date":474,"type":55},"2026-05-07",{"date":476,"type":21},"2026-05-30",{"date":478,"type":21},"2031-02-28",{"name":480,"class":62},"National Taiwan University Hospital",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":305,"sex":17,"minAge":134,"maxAge":135,"enrollmentInfo":487,"targetDuration":4,"studyType":73,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":63},"100615014","increasing-lung-cancer-screening-uptake-among-emergency-department-patients-100615014","NCT07287085","Increasing Lung Cancer Screening Uptake Among Emergency Department Patients","Inclusion Criteria:\n\n* Age 50 - 80\n* ≥ 20 pack-year smoking history\n* current smoker or quit within 15 years\n* English speaking\n* Current patient in URMC involved Emergency Department\n\nExclusion Criteria:\n\n* Non-English\n* Inability to provide consent (e.g. high clinical acuity, cognitive deficit)\n* Lack of text-capable mobile phone and\u002For inability to use text function\n* Not being a patient in URMC involved Emergency Department There are no restrictions for gender, racial and ethnic origins.",{"count":488,"type":21},349,[75],"The objective of the proposed clinical trial is to determine if we can increase LCS among ED patients using a combination of facilitated referral to an LCS program plus text message reminders to get screened. Step 1 of the approach is to identify participants that are eligible for LCS. Step 2 is to randomize eligible study participants between two study arms: (1) basic referral for LCS (i.e.\n\nverbal referral with written materials), and (2) facilitated referral for LCS (i.e. submission of a requisition to LCS program by staff) plus a subsequent series of text messages aimed at generating intention and motivation to get screened. The investigators' preliminary work showed this approach was feasible in the ED setting. The proposed study will build on this preliminary work with the goal of having a significant positive impact on LCS uptake.\n\nA total of 300 individuals eligible for LCS will be recruited from a high-volume urban ED, randomized between study arms, and followed-up at 120 days to assess interval LCS uptake. The Specific Aims of the proposed project are, (1) Compare LCS uptake between the two study arms, (2) Identify predictors of individuals that are not up-to-date with LCS at the time of enrollment, and (3) Evaluate study participant feedback on (a) barriers and facilitators to getting screened and (b) acceptability and appropriateness of ED-based promotion of LCS. The study team is at the forefront of developing ED-based interventions to promote cancer screening. This project leverages the universal access setting of the ED to identify individuals at greatest risk for lung cancer and get them screened. A scalable ED-based intervention that increases LCS uptake would save lives.",[492,25,284,142],"Screening Compliance",[494,495,496],"screening","lung cancer","screening compliance","2026-04-27",{"date":499,"type":55},"2026-05-04",{"date":501,"type":55},"2026-03-18",{"date":503,"type":21},"2028-11",{"name":505,"class":62},"University of Rochester",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":73,"phases":516,"briefSummary":517,"conditions":518,"keywords":529,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":63},"100634739","enhanced-copd-management-in-suspected-lung-cancer-patients-100634739","NCT07543601","Enhanced COPD Management in Suspected Lung Cancer Patients","Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention","ECHELON","Inclusion Criteria:\n\n* Undergoing diagnostic evaluation for suspected lung cancer\n* Spirometry showing obstructive airflow limitation (FEV₁\u002FFVC \\\u003C 75 % or FEV₁ \\\u003C 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation\n\nExclusion Criteria:\n\n* Presence of significant comorbidities that may interfere with diagnostic procedures or spirometry\n* Pregnant or breastfeeding women",{"count":515,"type":21},280,[75],"Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates.\n\nThis study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle.\n\nThe findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.",[519,25,520,521,522,523,524,525,526,263,527,528],"COPD (Chronic Obstructive Pulmonary Disease)","Lung Neoplasm Malignant","Lung Carcinoma","Pulmonary Neoplasms","Pulmonary Neoplasm","Pulmonary Cancers","Pulmonary Cancer","Pulmonary Carcinoma","COPD - Chronic Obstructive Pulmonary Disease","Airflow Obstruction, Chronic",[530,531,532,533],"Invesigation","Evaluation","Diagnostic Work-up","Diagnostic Pathway","2026-04-15",{"date":536,"type":55},"2026-04-22",{"date":538,"type":55},"2026-03-06",{"date":344,"type":21},{"name":541,"class":62},"Ditte Krag-Hansen",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":73,"phases":550,"briefSummary":551,"conditions":552,"keywords":554,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":63},"100634439","an-initial-experience-with-the-disposable-celsio-cryocatheter-system-for-diagnostic-and-interventional-bronchoscopy-100634439","NCT07539701","An Initial Experience With the Disposable Celsio Cryocatheter System for Diagnostic and Interventional Bronchoscopy","CELSIO","Inclusion Criteria:\n\n\\- Patient undergoing a bronchoscopic procedure with planned use of a 1.7mm cryocatheter\n\nExclusion Criteria:\n\n* Patient undergoing a bronchoscopic procedure with planned use of a different size cryocatheter (eg 1.1 or 2.4mm)\n* Current pregnancy or lactation\n* Lack of free and informed consent",{"count":331,"type":21},[75],"This clinical trial is intended for patients awaiting an interventional bronchoscopy procedure where the use of a cryocatheter is considered. This type of catheter is already used in clinical practice for the treatment of certain types of bronchial obstructions, including tumors, granulomas, and for foreign bodies extractions. This catheter uses extremely cold temperatures offering unique advantages compared to heat-based technologies. Different types of reusable and single-use cryocatheters are actually available on the market. This type of device requires the use of expensive and bulky consoles operating with heavy gas tanks, resulting in high maintenance costs. A Quebec, Canada based company has developed a cryocatheter that combines procedural efficacy with practical considerations in mind. The Celsio cryocatheter operates without a console and is designed to accommodate the bronchscopist through the different types of cryogenic procedures.\n\nThis study aims to generate meaningful, real-world evidence without interfering with standard clinical care. The collected data will serve to characterize the device's performance profile, identify best practices for its use, and provide data for the design of future prospective comparative studies.",[25,553],"Interstitial Lung Disease (ILD)",[555,556,557,558],"cryocathter","cryobiopsy","cryo-extraction","cryodevitalization","2026-04-13",{"date":561,"type":55},"2026-04-20",{"date":563,"type":21},"2026-03-23",{"date":565,"type":21},"2028-03-23",{"name":567,"class":62},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":576,"targetDuration":578,"studyType":22,"phases":4,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":296},"100631915","simplified-exercise-based-risk-assessment-in-lung-cancer-100631915","NCT07506889","Simplified Exercise-based Risk Assessment in Lung Cancer","EXercise-based Evaluation of Ventilatory Efficiency for enHanced Risk Assessment in Lungcancer trEatment Using End-tidal CO2: a Multicenter, Prospective Study","EXHALE-CO2","Inclusion Criteria:\n\n* Lung Cancer Diagnosis\n* Age of at least 18 years\n\nExclusion Criteria:\n\n* Not able to perform cycle ergometer exercise\n* Not able to understand spoken or written Swedish",{"count":577,"type":21},500,"1 Year","Physiological evaluation is part of the preoperative risk estimation in patients with lung cancer, and it aids in the choice of treatment. Ventilatory efficiency during exercise has emerged as a strong predictor of major postoperative complications, so far determined during a maximal cardiopulmonary exercise test. However, this test is limited by its availability and high cost, due to the requirement of high-technological equipment and advanced expertise. The current project aims to evaluate a simplified and accessible method for risk evaluation before decision on treatment in lung cancer. It builds on recent advances in technology and knowledge and combines a simple, low-intensity cycling test with measurement of ventilatory efficiency (end-tidal carbon dioxide pressure) with a handheld monitor. In a prospective, multi-center design the investigators will include patients evaluated for suspected lung cancer. The main objective is to establish threshold values for end-tidal carbon dioxide associated with low respectively high risk of major complications in patients undergoing surgery. In addition, the study aims to determine if end-tidal carbon dioxide can predict severe side-effects during neoadjuvant or curatively aiming systemic therapy. The project is closely linked to clinical practice, and the results can be easily implemented due to the simple and cost-efficient methodology. the suggested simplified approach would also allow access to physiological evaluation where more advanced methods are unavailable.",[25,368,581,582,583,584],"Surgery Complications","Neoadjuvant Chemoimmunotherapy","End-Tidal Carbon Dioxide","Exercise","2026-04-02",{"date":587,"type":55},"2026-04-08",{"date":589,"type":21},"2026-04-01",{"date":591,"type":21},"2029-12",{"name":593,"class":454},"Linkoeping University",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":604,"conditions":605,"keywords":608,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":272},"100632210","real-world-data-on-the-treatment-of-lung-cancer-patients-with-the-immune-checkpoint-inhibitor-tislelizumab-100632210","NCT07510724","Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab","Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab - the ReWoLuTe Study","IKF-ReWoLuTe","Inclusion criteria:\n\n* Patient has a histologically confirmed resectable Non-small cell lung cancer in stage II-IIIA with high risk of recurrence according to the 8th edition of the following AJCC staging criteria and is eligible for an R0 resection with curative intent and treatment with Tislelizumab in neoadjuvant and adjuvant setting:\n\n  1. Tumor size \\>4cm; or tumors of any size with either N1 or N2 status\n  2. Tumors invading thoracic structures (directly into the visceral pleura, parietal pleura, chest wall, main bronchus, phrenic nerve, mediastinal pleura, parietal pericardium)\n  3. Tumors \\>4cm that cause obstructive atelectasis extending to the hilum and involving parts of the lung, the entire lung or a main bronchus, regardless of the distance to the carina, or that invade the visceral pleura (PL1 or PL2)\n  4. Tumors with one or more separate nodules in the same lobe as the primary lung carcinoma.\n\n     OR\n\n     Patient has a histologically confirmed locally advanced or metastatic lung carcinoma of one of the following subtypes and is eligible for treatment with Tislelizumab in an approved indication:\n  5. NSCLC, squamous type, and the patient is not a candidate for surgical resection or platinum-based chemoradiation and did not receive prior treatment in palliative setting,\n  6. NSCLC, non-squamous type with PD-L1 expression on ≥50% of tumor cells and without EGFR- or ALK-positive mutations, and patient is not candidate for surgical resection or platinum-based chemoradiation and did not receive prior treatment in palliative setting,\n  7. NSCLC, squamous or non-squamous type, and the patient already received prior platinum-based therapy and, if with EGFR- or ALK-positive mutations, also has received targeted therapies,\n  8. SCLC, extensive-stage, and the patient has not received prior treatment in palliative setting.\n* A decision for treatment with an authorized Tislelizumab-based regimen has been made by the treating physician before enrolling into ReWoLuTe study.\n\nNOTE:\n\nPatients who have already received 1-2 cycles of therapy are still eligible for enrollment into the NIS. Patients who intended to be treated in the curative setting and had to switch before the start of an adjuvant treatment to the palliative setting or BSC (e.g. due to progress or other reasons), will not be excluded from study.\n\nExclusion criteria:\n\n* The patient has not provided signed informed consent.\n* The patient is under 18 years of age at the time of providing signed informed consent.\n* The patient is unable to fully comprehend the implications of study participation.",{"count":603,"type":21},240,"The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.",[606,607,25],"Small Cell Lung Cancer (SCLC)","Non-Small Cell Lung Cancer (NSCLC)",[142,609,610,611,612,613],"Tislelizumab-based therapy","real-world data on tislelizumab treated patients","resectable NSCLC (perioperative setting)","locally advanced or metastatic NSCLC (1st\u002F2nd line)","extensive-stage SCLC (1st line)","2026-03-30",{"date":616,"type":55},"2026-04-03",{"date":618,"type":55},"2025-12-23",{"date":620,"type":21},"2033-01-23",{"name":622,"class":62},"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":305,"sex":17,"minAge":630,"maxAge":4,"enrollmentInfo":631,"targetDuration":4,"studyType":73,"phases":633,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":646},"100628761","prospective-multicentre-study-for-the-application-of-telomere-measurement-technology-as-a-tool-for-lung-cancer-diagnosis-100628761","NCT07465848","Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis","PneumoTAV001","Inclusion Criteria:\n\nCase Group:\n\n* Person aged 45 years or older at the time of signing the consent form.\n* Person with a current anatomopathologically confirmed diagnosis of small-cell or non-small cell lung cancer.\n* Not having received any oncological treatment prior to sample collection (surgery, radiotherapy, or systemic treatment with chemotherapy or immunotherapy).\n\nControl Group:\n\nCohort A (High risk controls):\n\n* Person aged 45 years or older at the time of signing the consent form.\n* High risk of lung cancer, defined as having a smoking history of at least 20 pack-year and currently smoking or having quit within the past 15 years.\n* No diagnosis or suspicion of lung cancer. Asymptomatic individuals who have undergone a chest computed tomography (CT) scan for lung cancer screening within the 12 months prior to signing the informed consent and as part of routine clinical practice, with a LUNG-RADS score of 3 or lower, will be included.\n\nCohort B (Low-risk controls):\n\n* Person aged 45 years or older at the time of signing the consent form.\n* Without high risk of lung cancer according to the criteria defined in cohort A.\n* No diagnosis or suspicion of lung cancer.\n\nExclusion Criteria:\n\n* History of any malignant neoplasm, except for subjects with tumors in localized stages who have undergone radical treatment and have been disease-free for at least five years.\n* Patient diagnosed with lung cancer who has already started oncological treatment before sample collection.\n* Patient who has undergone a biopsy or any invasive procedure or minor surgery less than 48 hours ago.\n* Patient who has undergone major surgery less than 7 days ago.\n* Patient with severe chronic kidney disease, defined as a glomerular filtration rate below 15 ml\u002Fmin.\n* Patient with severe liver disease, defined as Child-Pugh C.\n* Active infection, or treated less than 4 weeks ago.\n* Vulnerable population, for example, minors, prisoners, pregnant women, adults physically or mentally incapable of giving consent.","45 Years",{"count":632,"type":21},1200,[75],"This research is a clinical performance study of in vitro diagnostic device (IVD), a prospective, multicentre, open-label, case-control clinical investigation aimed at constructing a predictive model that allows results to be classified as positive or negative in relation to the probability of having lung cancer.",[25,636,637],"Health Adult Subjects","Patient",{"date":639,"type":55},"2026-03-12",{"date":641,"type":55},"2025-10-08",{"date":643,"type":21},"2026-12-31",{"name":645,"class":62},"Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)",12,{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":654,"targetDuration":656,"studyType":22,"phases":4,"briefSummary":657,"conditions":658,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":63},"100626773","study-of-risk-factors-and-prediction-of-blood-clots-after-lung-cancer-surgery-100626773","NCT07439991","Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery","Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients undergoing surgical resection for lung cancer\n3. Postoperative hospital stay ≥ 48 hours\n4. Availability of perioperative clinical, laboratory, and imaging data\n5. Willingness to provide informed consent and participate in 30-day follow-up\n\nExclusion Criteria:\n\n1. Pre-existing deep vein thrombosis (DVT) or pulmonary embolism (PE) before surgery\n2. Preoperative or ongoing anticoagulation therapy for ≥ 2 weeks\n3. Severe coagulation disorders or bleeding diseases\n4. Severe hepatic, renal, or hematologic dysfunction, or uncontrolled systemic infection\n5. Concurrent major organ surgery (e.g., cardiac, liver surgery)\n6. Pregnancy or lactation\n7. Incomplete postoperative follow-up data",{"count":655,"type":21},900,"30 Days","The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is:\n\nWhich clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk?\n\nParticipants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.",[25,659,660],"Deep Vein Thrombosis (DVT)","Venous Thromboembolism (VTE)","2026-02-23",{"date":663,"type":55},"2026-02-27",{"date":665,"type":55},"2024-11-01",{"date":667,"type":21},"2029-11-30",{"name":669,"class":62},"The First Hospital of Jilin University",{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":676,"eligibilityCriteria":677,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":678,"targetDuration":4,"studyType":73,"phases":680,"briefSummary":683,"conditions":684,"keywords":697,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":710,"lastUpdatePostDateStruct":711,"startDateStruct":713,"completionDateStruct":715,"leadSponsor":717,"locationsCount":63},"100624518","phase-1-ebnk-001-allogeneic-nk-cells-with-low-dose-il-15--pembrolizumab-in-advanced-solid-tumors-100624518","NCT07410676","EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","An Open-Label Phase 1\u002F2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide\u002FFludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors","EBNK-ST-001","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed advanced\u002Fmetastatic solid tumor that is relapsed\u002Frefractory after standard therapy (or no standard therapy available).\n* Measurable disease per RECIST v1.1 (or iRECIST if applicable).\n* ECOG performance status 0-1 (or 0-2 as allowed).\n* Adequate organ function (thresholds modeled on NK protocols):\n* Platelets ≥ 75,000\u002FµL; hemoglobin ≥ 9 g\u002FdL; ANC ≥ 1,000\u002FµL (unsupported by growth factors\u002Ftransfusions as defined).\n* eGFR ≥ 60 mL\u002Fmin\u002F1.73m².\n* AST\u002FALT ≤ 3× ULN.\n* Oxygen saturation ≥ 90% on room air (with PFT requirements if indicated).\n* LVEF ≥ 40% (by ECHO\u002FMUGA\u002FCMR).\n* If brain metastases are present, they must be stable for a defined period (example: ≥3 months) and not requiring escalating steroids.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Any condition requiring systemic immunosuppression (e.g., \\>5 mg prednisone\u002Fday or equivalent) during dosing window (topical\u002Finhaled may be allowed).\n* Active autoimmune disease requiring systemic immunosuppression.\n* Uncontrolled bacterial, fungal, or viral infection.\n* Receipt of investigational agent within 28 days before first study drug.\n* Live vaccine within 6 weeks prior to lymphodepletion.\n* Known HIV positivity or active hepatitis B\u002FC with detectable viral load (protocol may allow chronic asymptomatic hepatitis depending on risk plan).\n* Known allergy to investigational product components (example: albumin\u002Fhuman or DMSO).\n* Any medical\u002Fsocial condition likely to interfere with study compliance or increase risk.",{"count":679,"type":21},83,[681,682],"PHASE1","PHASE2","This Phase 1\u002F2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide\u002Ffludarabine (CY\u002FFLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced\u002Fmetastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.",[685,32,686,687,25,688,689,690,691,692,203,693,694,695,696],"Cancer","Leukaemia","Breast Cancer (Locally Advanced or Metastatic)","Colorectal Cancer","Melanoma (Skin Cancer)","Bladder Cancer","Kidney Cancer","Pancreatic Cancer Metastatic","Ovarian Cancer","Esophageal Cancer","Glioblastoma","Non-Melanoma Skin Cancer",[698,699,700,701,29,702,703,704,705,696,706,690,707,708,709,694],"Natural killer cells","NK cell therapy","Solid tumors","IL-15","Lung and Bronchus Cancer","Prostate Cancer","Colorectal (Colon and Rectal) Cancer","CAR-T","Melanoma","Kidney (Renal Cell and Renal Pelvis) Cancer","Pancreatic Cancer","Stomach (Gastric) Cancer","2026-02-14",{"date":712,"type":55},"2026-02-18",{"date":714,"type":55},"2026-02-01",{"date":716,"type":21},"2029-12-21",{"name":718,"class":62},"Essen Biotech",{"id":720,"slug":721,"hasResults":12,"nctId":722,"briefTitle":723,"officialTitle":724,"acronym":4,"eligibilityCriteria":725,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":726,"targetDuration":4,"studyType":73,"phases":727,"briefSummary":728,"conditions":729,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":730,"lastUpdatePostDateStruct":731,"startDateStruct":732,"completionDateStruct":734,"leadSponsor":736,"locationsCount":63},"100625116","discrimination-of-n2a-and-n2b-by-ebus-tbna-is-a-change-of-the-needle-necessary-100625116","NCT07418450","Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?","Discrimination of N2a and N2b by EBUS-TBNA: is a Needle Change Necessary? - a Prospective Pilot Study","Inclusion Criteria:\n\n* Pulmonary lesion suspicious for lung cancer or histologically confirmed lung cancer\n* indication for mediastinal staging\n\nExclusion Criteria:\n\n\\-",{"count":331,"type":21},[75],"During EBUS staging in patients with mediastinal lymphadenopathy, it is planned to perform a first round of staging with change of the needle between all lymph nodes and a second round of staging without change of the needle.",[25],"2026-02-10",{"date":712,"type":55},{"date":733,"type":55},"2025-11-05",{"date":735,"type":21},"2027-05",{"name":737,"class":62},"University of Vienna",{"id":739,"slug":740,"hasResults":12,"nctId":741,"briefTitle":742,"officialTitle":743,"acronym":744,"eligibilityCriteria":745,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":746,"targetDuration":747,"studyType":22,"phases":4,"briefSummary":748,"conditions":749,"keywords":750,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":755,"lastUpdatePostDateStruct":756,"startDateStruct":757,"completionDateStruct":759,"leadSponsor":761,"locationsCount":63},"100623636","noninvasive-detection-of-lung-nodule-malignancy-using-cfdna-fragmentomics-100623636","NCT07399210","Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics","A Prospective Clinical Study Evaluating the Noninvasive Use of Circulating Cell-Free DNA Fragmentomics to Differentiate Benign and Malignant Lung Nodules, With Emphasis on Small Nodules.","SHC2408","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Positive for lung nodules on low-dose spiral CT (LDCT) meeting one of the following criteria:\n\nSolid or part-solid nodules ≥ 5 mm and ≤ 20 mm; Pure ground-glass nodules ≥ 8 mm and ≤ 30 mm; In cases of multiple nodules, the largest nodule (by maximum diameter) must meet these criteria;\n\n* Participants whose lung nodule status (benign or malignant) can be clinically confirmed;\n* No cancer-directed therapy (e.g., chemotherapy, radiotherapy, immunotherapy, cell therapy) within the past 3 months;\n* Able to provide a 5 mL peripheral blood sample prior to any treatment;\n* Voluntary signing of informed consent after full explanation of the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding;\n* Current or past diagnosis (within the past 5 years) of malignant tumors (excluding patients with early-stage lung cancer who have undergone surgery but still have multiple evaluable nodules), or with severe heart disease, serious liver or kidney disorders, or significant bone marrow hematopoietic dysfunction;\n* History of organ transplantation or blood transfusion within the past 3 months;\n* History of seropositivity for human immunodeficiency virus (HIV);\n* Any other condition deemed inappropriate for study participation by the investigators.",{"count":603,"type":21},"1 Month","The goal of this observational study is to learn if cfDNA fragmentomics can noninvasively diagnose whether lung nodules are benign or malignant in adults with imaging-detected lung nodules.",[25,312],[312,751,752,753,754],"Lung Cancer(Diagnosis)","cfDNA","Small Nodule","Non-invasive","2026-02-08",{"date":730,"type":55},{"date":758,"type":55},"2024-08-21",{"date":760,"type":21},"2026-08-21",{"name":762,"class":62},"Baohui Han"]